Apeloa Pharmaceutical Co Ltd (000739) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apeloa Pharmaceutical Co Ltd (000739) has a cash flow conversion efficiency ratio of 0.070x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥446.18 Million ≈ $65.29 Million USD) by net assets (CN¥6.35 Billion ≈ $928.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 000739 market cap for the company's overall valuation and market capitalisation.
Apeloa Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Apeloa Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Apeloa Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apeloa Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore Apeloa Pharmaceutical Co Ltd (000739) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hyundai Motor Co Pref
KO:005387
|
-0.039x |
|
Kilroy Realty Corp
NYSE:KRC
|
0.014x |
|
Yonghui Superstores Co Ltd
SHG:601933
|
-0.036x |
|
AZZ Incorporated
NYSE:AZZ
|
0.027x |
|
Banco del Bajío S.A. Institución de Banca Múltiple
MX:BBAJIOO
|
0.304x |
|
Vontobel Holding
SW:VONN
|
0.544x |
|
TRI Pointe Homes Inc
NYSE:TPH
|
0.067x |
|
Cochin Shipyard Limited
NSE:COCHINSHIP
|
-0.121x |
Annual Cash Flow Conversion Efficiency for Apeloa Pharmaceutical Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Apeloa Pharmaceutical Co Ltd from 1998 to 2025. View 000739 share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥6.35 Billion ≈ $928.67 Million |
CN¥1.23 Billion ≈ $180.09 Million |
0.194x | +8.29% |
| 2024-12-31 | CN¥6.75 Billion ≈ $987.72 Million |
CN¥1.21 Billion ≈ $176.88 Million |
0.179x | +8.18% |
| 2023-12-31 | CN¥6.23 Billion ≈ $911.71 Million |
CN¥1.03 Billion ≈ $150.92 Million |
0.166x | -31.10% |
| 2022-12-31 | CN¥5.52 Billion ≈ $807.64 Million |
CN¥1.33 Billion ≈ $194.05 Million |
0.240x | +98.74% |
| 2021-12-31 | CN¥5.06 Billion ≈ $740.44 Million |
CN¥611.75 Million ≈ $89.52 Million |
0.121x | -49.90% |
| 2020-12-31 | CN¥4.39 Billion ≈ $642.49 Million |
CN¥1.06 Billion ≈ $155.04 Million |
0.241x | -33.15% |
| 2019-12-31 | CN¥3.77 Billion ≈ $551.37 Million |
CN¥1.36 Billion ≈ $199.02 Million |
0.361x | +45.01% |
| 2018-12-31 | CN¥3.35 Billion ≈ $489.52 Million |
CN¥832.69 Million ≈ $121.85 Million |
0.249x | +261.87% |
| 2017-12-31 | CN¥3.05 Billion ≈ $446.31 Million |
CN¥209.80 Million ≈ $30.70 Million |
0.069x | -0.24% |
| 2016-12-31 | CN¥2.62 Billion ≈ $382.88 Million |
CN¥180.42 Million ≈ $26.40 Million |
0.069x | -62.22% |
| 2015-12-31 | CN¥2.42 Billion ≈ $353.65 Million |
CN¥441.16 Million ≈ $64.56 Million |
0.183x | -46.49% |
| 2014-12-31 | CN¥2.31 Billion ≈ $337.43 Million |
CN¥786.64 Million ≈ $115.11 Million |
0.341x | +232.78% |
| 2013-12-31 | CN¥1.86 Billion ≈ $271.86 Million |
CN¥190.45 Million ≈ $27.87 Million |
0.103x | -58.33% |
| 2012-12-31 | CN¥1.37 Billion ≈ $199.83 Million |
CN¥335.90 Million ≈ $49.15 Million |
0.246x | -25.14% |
| 2011-12-31 | CN¥1.23 Billion ≈ $180.21 Million |
CN¥404.62 Million ≈ $59.21 Million |
0.329x | +119.48% |
| 2010-12-31 | CN¥808.57 Million ≈ $118.32 Million |
CN¥121.05 Million ≈ $17.71 Million |
0.150x | -42.88% |
| 2009-12-31 | CN¥794.78 Million ≈ $116.30 Million |
CN¥208.30 Million ≈ $30.48 Million |
0.262x | +112.87% |
| 2008-12-31 | CN¥768.11 Million ≈ $112.40 Million |
CN¥94.57 Million ≈ $13.84 Million |
0.123x | -46.98% |
| 2007-12-31 | CN¥750.11 Million ≈ $109.76 Million |
CN¥174.20 Million ≈ $25.49 Million |
0.232x | -36.48% |
| 2006-12-31 | CN¥436.05 Million ≈ $63.81 Million |
CN¥159.43 Million ≈ $23.33 Million |
0.366x | +72.33% |
| 2005-12-31 | CN¥411.93 Million ≈ $60.28 Million |
CN¥87.40 Million ≈ $12.79 Million |
0.212x | +65.59% |
| 2004-12-31 | CN¥371.08 Million ≈ $54.30 Million |
CN¥47.54 Million ≈ $6.96 Million |
0.128x | -60.01% |
| 2003-12-31 | CN¥328.83 Million ≈ $48.12 Million |
CN¥105.36 Million ≈ $15.42 Million |
0.320x | +3243.46% |
| 2002-12-31 | CN¥293.69 Million ≈ $42.98 Million |
CN¥2.81 Million ≈ $411.85K |
0.010x | +536.80% |
| 2001-12-31 | CN¥259.70 Million ≈ $38.00 Million |
CN¥-569.79K ≈ $-83.38K |
-0.002x | -108.50% |
| 2000-12-31 | CN¥274.23 Million ≈ $40.13 Million |
CN¥7.08 Million ≈ $1.04 Million |
0.026x | +138.74% |
| 1999-12-31 | CN¥307.93 Million ≈ $45.06 Million |
CN¥-20.52 Million ≈ $-3.00 Million |
-0.067x | -150.12% |
| 1998-12-31 | CN¥226.31 Million ≈ $33.12 Million |
CN¥30.10 Million ≈ $4.40 Million |
0.133x | -- |
About Apeloa Pharmaceutical Co Ltd
Apeloa Pharmaceutical Co.,Ltd provides raw materials various pharmaceutical factories in the People's Republic of China and internationally. The company operates through API, CDMO, and Pharmaceutical segments. It offers API intermediates business, which includes cephalosporin, penicillin, psychotropic, cardiovascular and cerebrovascular, and veterinary API intermediates series; innovative drug R&… Read more